1. Scully M., Cataland S., Coppo P., et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312–22. DOI:10.1111/JTH.13571.
2. Cuker A., Cataland S.R., Coppo P., et al. Redefining Outcomes in Immune TTP: an International Working Group Consensus Report. Blood. 2021;137(14):1855–61. DOI:10.1182/blood.2020009150.
3. Sadler J.E. Pathophysiology of thrombotic thrombocytopenic purpura. Blood. 2017;130(10):1181–8. DOI:10.1182/BLOOD-2017-04-636431.
4. Hosler G.A., Cusumano A.M., Hutchins G.M. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med. 2003;127(7):834–9. DOI:10.5858/2003-127-834-TTPAHU.
5. Ridolfi R.L., Hutchins G.M., Bell W.R. The heart and cardiac conduction system in thrombotic thrombocytopenic purpura. A clinicopathologic study of 17 autopsied patients. Ann Intern Med. 1979;91(3):357–63. DOI:10.7326/0003-4819-91-3-357.
6. Roriz M., Landais M., Desprez J., et al. Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura. Medicine (Baltimore). 2015;94(42):e1598. DOI:10.1097/MD.0000000000001598.
7. van Dorland H.A., Taleghani M.M., Sakai K., et al. The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017. Haematologica. 2019;104(10):2107–15. DOI:10.3324/HAEMATOL.2019.216796.
8. Fakhouri F. Pregnancy-related thrombotic microangiopathies: Clues from complement biology. 2016;54(2):199–202.
9. Moatti-Cohen M., Garrec C., Wolf M., et al. Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura. Blood. 2012;119(24):5888–97. DOI:10.1182/BLOOD-2012-02-408914.
10. Mariotte E., Azoulay E., Galicier L., et al. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): A cross-sectional analysis of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(5):e237–45. DOI:10.1016/S2352-3026(16)30018-7.
11. Morgand M., Buffet M., Busson M., et al. High prevalence of infectious events in thrombotic thrombocytopenic purpura and genetic relationship with toll-like receptor 9 polymorphisms: experience of the French Thrombotic Microangiopathies Reference Center. Transfusion. 2014;54(2):389–97. DOI:10.1111/TRF.12263.
12. Wang Z., Yu Z., Su J., et al. Sepsis-induced disseminated intravascular coagulation with features of thrombotic thrombocytopenic purpura: a fatal fulminant syndrome. Clin Appl Thromb Hemost. 2011;17(3):251–3. DOI:10.1177/1076029609357739.
13. Douglas K.W., Pollock K.G., Young D., et al. Infection frequently triggers thrombotic microangiopathy in patients with preexisting risk factors: a single-institution experience. J Clin Apher. 2010;25(2):47–53. DOI:10.1002/JCA.20226.
14. Levy G.G., Nichols W.C., Lian E.C., et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413(6855):488–94. DOI:10.1038/35097008.
15. Fujimura Y., Matsumoto M., Isonishi A., et al. Natural history of Upshaw-Schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011;9 Suppl 1(1 S):283–301. DOI:10.1111/J.1538-7836.2011.04341.X.
16. Lotta L.A., Wu H.M., Mackie I.J., et al. Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood. 2012;120(2):440–8. DOI:10.1182/BLOOD-2012-01-403113.
17. George J.N. Forecasting the future for patients with hereditary TTP. Blood. 2012;120(2):243–4. DOI:10.1182/BLOOD-2012-05-427419.
18. Page E.E., Kremer Hovinga J.A., Terrell D.R., et al. Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015. Blood Adv. 2017;1(10):590–600. DOI:10.1182/BLOODADVANCES.2017005124.
19. Blombery P., Kivivali L., Pepperell D., et al. Diagnosis and management of thrombotic thrombocytopenic purpura (TTP) in Australia: findings from the first 5 years of the Australian TTP/thrombotic microangiopathy registry. Intern Med J. 2016;46(1):71–9. DOI:10.1111/IMJ.12935.
20. Joly B.S., Stepanian A., Leblanc T., et al. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Lancet Haematol. 2016;3(11):e537–46. DOI:10.1016/S2352-3026(16)30125-9.
21. Amorosi E.L., Ultman J.E. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine (Baltimore). 1966;45(3):139–59.
22. Chiasakul T., Cuker A. Clinical and laboratory diagnosis of TTP: an integrated approach. Hematol Am Soc Hematol Educ Progr. 2018;2018(1):530–8. DOI:10.1182/ASHEDUCATION-2018.1.530.
23. Amalakuhan B., Nambiar A.M. Diagnosis and Management of Thrombotic Thrombocytopenic Purpura. Evidence-Based Crit Care A Case Study Approach. 2017;605–13. DOI:10.1007/978-3-319-43341-7_70.
24. Azoulay E., Bauer P.R., Mariotte E., et al. Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura. Intensive Care Med. 2019;45(11):1518–39. DOI:10.1007/S00134-019-05736-5.
25. Benhamou Y., Boelle P.Y., Baudin B., et al. Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center. J Thromb Haemost. 2015;13(2):293–302. DOI:10.1111/JTH.12790.
26. Meloni G., Proia A., Antonini G., et al. Thrombotic thrombocytopenic purpura: prospective neurologic, neuroimaging and neurophysiologic evaluation. Haematologica. 2001;86(11):1194–9.